Cardinal Health, Inc. (CAH) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $230.96 (+1.71%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 8, 2026 | Elizabeth Anderson | Evercore ISI | $240.00 | +3.9% |
| Mar 9, 2026 | Michael Cherny | Leerink Partners | $275.00 | +19.1% |
| Feb 6, 2026 | Kevin Caliendo | UBS | $260.00 | +12.6% |
| Feb 6, 2026 | Steven Valiquette | Mizuho Securities | $235.00 | +1.7% |
| Feb 5, 2026 | Elizabeth Anderson | Evercore ISI | $260.00 | +12.6% |
| Jan 29, 2026 | Erin Wright | Morgan Stanley | $245.00 | +6.1% |
| Jan 14, 2026 | Eric Coldwell | Robert W. Baird | $250.00 | +8.2% |
| Jan 13, 2026 | Michael Cherny | Leerink Partners | $240.00 | +3.9% |
| Jan 12, 2026 | Steven Valiquette | Mizuho Securities | $222.00 | -3.9% |
| Dec 8, 2025 | Glen Santangelo | Barclays | $243.00 | +5.2% |
| Nov 3, 2025 | Steven Valiquette | Mizuho Securities | $210.00 | -9.1% |
| Oct 31, 2025 | Elizabeth Anderson | Evercore ISI | $220.00 | -4.7% |
| Aug 12, 2025 | Michael Cherny | Leerink Partners | $186.00 | -19.5% |
| Aug 12, 2025 | Brian Tanquilut | Jefferies | $150.00 | -35.1% |
| Jun 13, 2025 | Erin Wright | Morgan Stanley | $181.00 | -21.6% |
| Jun 3, 2025 | Stephen Baxter | Wells Fargo | $179.00 | -22.5% |
| Feb 4, 2025 | Kristina Ruggeri | Argus Research | $148.00 | -35.9% |
| Sep 23, 2024 | Eric Coldwell | Robert W. Baird | $140.00 | -39.4% |
| Sep 11, 2024 | David Toung | Argus Research | $125.00 | -45.9% |
| Aug 16, 2024 | George Hill | Deutsche Bank | $119.00 | -48.5% |
Top Analysts Covering CAH
CAH vs Sector & Market
| Metric | CAH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.14 | 2.25 | 2.42 |
| Analyst Count | 14 | 8 | 19 |
| Target Upside | +10.5% | +16316.2% | +17.1% |
| P/E Ratio | 35.31 | 2.98 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $68.51B | $70.03B | $72.90B | 4 |
| 2026-12-31 | $70.33B | $71.89B | $74.84B | 8 |
| 2027-03-31 | $66.54B | $68.02B | $70.81B | 4 |
| 2027-06-30 | $71.24B | $72.82B | $75.80B | 4 |
| 2027-09-30 | $75.63B | $77.31B | $80.48B | 5 |
| 2027-12-31 | $77.96B | $79.69B | $82.95B | 4 |
| 2028-03-31 | $73.39B | $75.02B | $78.09B | 3 |
| 2028-06-30 | $77.51B | $79.23B | $82.47B | 3 |
| 2029-06-30 | $330.25B | $335.48B | $343.28B | 9 |
| 2030-06-30 | $372.31B | $378.20B | $386.99B | 12 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $2.74 | $2.82 | $2.97 | 4 |
| 2026-12-31 | $2.84 | $2.93 | $3.08 | 4 |
| 2027-03-31 | $3.09 | $3.18 | $3.35 | 4 |
| 2027-06-30 | $2.60 | $2.68 | $2.82 | 4 |
| 2027-09-30 | $3.22 | $3.31 | $3.49 | 4 |
| 2027-12-31 | $3.27 | $3.37 | $3.55 | 4 |
| 2028-03-31 | $3.43 | $3.53 | $3.72 | 5 |
| 2028-06-30 | $3.05 | $3.14 | $3.31 | 5 |
| 2029-06-30 | $14.64 | $14.94 | $15.39 | 1 |
| 2030-06-30 | $17.02 | $17.37 | $17.89 | 1 |
Frequently Asked Questions
What is the analyst consensus for CAH?
The consensus among 14 analysts covering Cardinal Health, Inc. (CAH) is Buy with an average price target of $253.38.
What is the highest price target for CAH?
The highest price target for CAH is $275.00, set by Michael Cherny at Leerink Partners on 2026-03-09.
What is the lowest price target for CAH?
The lowest price target for CAH is $51.00, set by George Hill at Deutsche Bank on 2022-05-08.
How many analysts cover CAH?
14 analysts have issued ratings for Cardinal Health, Inc. in the past 12 months.
Is CAH a buy or sell right now?
Based on 14 analyst ratings, CAH has a consensus rating of Buy (2.14/5) with a +10.5% upside to the consensus target of $253.38.
What are the earnings estimates for CAH?
Analysts estimate CAH will report EPS of $2.82 for the period ending 2026-09-30, with revenue estimated at $70.03B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.